SS-31 (elamipretide) has a clear trial dose to anchor to: 40 mg subcutaneously once daily. That is the regimen used in the MMPOWER-3 primary mitochondrial myopathy trial and in the FORZINITY product approved for Barth syndrome in 2025.[1][2]
Reviewed for accuracy · Last reviewed July 7, 2026The important context is that this dose is tied to specific clinical settings, and the compound's results were mixed: it gained a narrow accelerated approval for Barth syndrome on a muscle-strength endpoint, while the larger mitochondrial myopathy trial did not meet its primary endpoints. Research use outside those indications has no established dose, and independently sourced material carries no guarantee of the testing an approved product does.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting any compound.